Coiled Therapeutics plc (AIM:COIL)
London · Delayed Price · Currency is GBP · Price in GBX 6.55
-0.05 (-0.76%)
At close: Oct 13, 2026
Coiled Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Coiled Therapeutics presented strong early clinical data for its novel TAC3-targeting oncology program, highlighting robust efficacy, safety, and brain penetration across multiple solid tumors. The company is expanding indications, advancing a secondary STAT-6 program, and expects key data and partnership catalysts within the next year.
Fiscal Year 2025
-
The acquisition accelerates the transition to a clinical-stage company, bringing a first-in-class oncology therapy (AO-252) and securing GBP 6 million in funding. Integration of A2A’s team and AI platform, plus a move to AIM, positions the company for growth in a multi-billion dollar market.